Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Emerging drug targets for antiretroviral therapy.

Reeves JD, Piefer AJ.

Drugs. 2005;65(13):1747-66. Review.

PMID:
16114975
2.
3.

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Castagna A, Biswas P, Beretta A, Lazzarin A.

Drugs. 2005;65(7):879-904.

PMID:
15892586
4.

Virus entry as a target for anti-HIV intervention.

Esté JA.

Curr Med Chem. 2003 Sep;10(17):1617-32. Review.

PMID:
12871111
5.

Novel targets for antiretroviral therapy: clinical progress to date.

Dau B, Holodniy M.

Drugs. 2009;69(1):31-50. doi: 10.2165/00003495-200969010-00003. Review.

PMID:
19192935
6.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
7.

The HIV entry inhibitors revisited.

Leonard JT, Roy K.

Curr Med Chem. 2006;13(8):911-34. Review.

PMID:
16611075
8.

Cellular entry of HIV: Evaluation of therapeutic targets.

Pöhlmann S, Reeves JD.

Curr Pharm Des. 2006;12(16):1963-73. Review.

PMID:
16787241
10.

New antiretroviral drugs.

Gulick RM.

Clin Microbiol Infect. 2003 Mar;9(3):186-93. Review.

11.

Evaluation of current approaches to inhibit HIV entry.

Pöhlmann S, Doms RW.

Curr Drug Targets Infect Disord. 2002 Mar;2(1):9-16. Review.

PMID:
12462149
12.
13.

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.

Jiang X, Feyertag F, Meehan CJ, McCormack GP, Travers SA, Craig C, Westby M, Lewis M, Robertson DL.

J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 2015 Sep 2.

14.
15.

[Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].

Azevedo-Pereira JM, Santos-Costa Q.

Acta Med Port. 2008 Sep-Oct;21(5):497-504. Epub 2009 Jan 16. Review. Portuguese.

16.

HIV entry and fusion inhibitors.

Chantry D.

Expert Opin Emerg Drugs. 2004 May;9(1):1-7. Review.

PMID:
15155132
17.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
18.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

19.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
20.

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.

Pugach P, Ketas TJ, Michael E, Moore JP.

Virology. 2008 Aug 1;377(2):401-7. doi: 10.1016/j.virol.2008.04.032. Epub 2008 Jun 2.

Supplemental Content

Support Center